You just read:

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

News provided by

Epygenix Therapeutics, Inc.

Jun 24, 2019, 10:05 ET